Publicador de contenidos

Investigación e Innovación Programas
Investigación, Eliminación de la malaria

BOHEMIA

Broad One Health Endectocide-based Malaria Intervention in Africa

Duración
Feb 2019 - Feb 2024
Coordinador
Regina Rabinovich
Financiadores
UNITAID
Página web
http://bohemiaconsortium.org

The world is not on track to achieve the goals proposed by WHO in the Global Technical Strategy for Malaria 2016-2030 (GTS), and currently available tools are unlikely to suffice. Vector control, our most effective strategy, is now doubly threatened by widespread insecticide resistance and residual transmission caused by mosquito behavioral adaptations that allow them to elude home-based vector control tools such as treated bed nets and indoor residual spraying.

Ivermectin is an antiparasitic drug distributed to more than 2.5 billion people over the last 30 years in mass drug administration campaigns to directly treat two Neglected Tropical Diseases (NTDs). More recently, it has been noted that ivermectin can also increase the mortality of mosquitoes that feed on treated humans or animals during a time period that can be up to 28 days, depending on the dose. 

Thus, Mass Drug Administration (MDA) of ivermectin to humans and/or livestock holds potential to complement the malaria toolbox by tackling residual transmission and help the malaria community get back on track to achieve the GTS goals.

Objectives

BOHEMIA will evaluate the MDA of ivermectin to humans and/or livestock in two African countries - Mozambique and Kenya - during the malaria season, and will collect data on the epidemiological impact to support normative guidance, global and national policy change.

Should evidence be supportive, engagement with WHO and other key stakeholders will support the conditions for a policy recommendation, and subsequent national adoption.

BOHEMIA combines evidence generation and stakeholder engagement to enable the path for policy and implementation of ivermectin as a new vector control tool complementary to standard tools (treated bed nets and indoor residual spraying).

The Consortium

The BOHEMIAconsortium is led by ISGlobal and includes:

The MDA is being implemented in Mozambique by the Centro de Investigação em Saúde de Manhiça (CISM), and in Kenya by the Kenya Medical Research Institute in collaboration with the KEMRI | Wellcome Trust research program.

 

Total funding

25.3 U$ million (awarded by Unitaid)

 

Nuestro equipo

Principal Investigator

Co-Principal Investigator

  • CARLOS CHACCOUR
    CARLOS CHACCOUR Assistant Research Professor. Coinvestigador principal y director científico del proyecto BOHEMIA. Malaria, Virus emergentes

ISGlobal team

Ver más

Otros proyectos

Ver proyectos pasados

NHEPACHA

Nuevas Herramientas para el Diagnóstico y la Evaluación del Paciente con Enfermedad de Chagas

Estudio inmunológico de la vacuna RTS,S

Estudio de correlatos de protección frente a la malaria después de la vacunación con RTS,S/AS01E: Una evaluación inmunológica exhaustiva en el ensayo clínico de Fase III, doble ciego, aleatorizado, multicéntrico con un grupo control

Euroleish.net

Control of Leishmaniasis. From bench to bedside and community

GREPIMER

Grup de recerca en patología importada i malaties emergents i re-emergents

TESEO

Nuevos regímenes de quimioterapia y biomarcadores para la enfermedad de Chagas

ASINTMAL

Unravelling Disease Tolerance and Host Resistance in Afebrile 'P. falciparum' Infections: a Prospective Study in Mozambican Adults

ADAM

Administración masiva y focal de fármacos antimaláricos para avanzar hacia la eliminación de la malaria en Mozambique: acelerando la implementación de programas y políticas

Science4Pandemics

Citizens engagement digital platform for collective intelligence in pandemics

HIDDENVIVAX

Novel organ-on-a-chip technology to study extracellular vesicles-mediated cryptic infections in Plasmodium vivax malaria

EpiGen

Building Scalable Pathogen Genomic Epidemiology in Ethiopia

MalTransc

Transcriptional regulation of adaptation and developmental decisions in malaria parasites: from epigenetic variation to directed transcriptional responses

RESPONSE

Mechanisms of the transcriptional responses to changes in the environment in the malaria parasite Plasmodium falciparum

VivaxEVTalk

Extracellular Vesicles as Intercellular Communicators and Biomarkers of Cryptic Erythrocytic Infections in Plasmodium vivax malaria

VaMonoS

Unravelling the heterogoneity and function of monocytes in vaccination and immunity to malaria

CLIMSOCTRYPBOL

Insight on climate and social participatory research for integral management of vectorborne zoonosis caused by Trypanosoma cruzi and Leishmania spp. in the Bolivian Gran Chaco.

SexMal

Social affairs and sex in P. falciparum: implications for malaria elimination

MENA Migrant Health

Transforming data collection and surveillance to drive migrant health research, care and policy

MESA

La Alianza Científica para la Erradicación de la Malaria (MESA) tiene como objetivo avanzar en la ciencia de la erradicación de la malaria.

SMART

Identifying Severe Malaria with a new Aptamer-based Rapid diagnostic Test

GlycoTargets

Nuevas terapias antimaláricas dirigidas contra las vías de glicosilación de 'Plasmodium falciparum'

GenMoz

P. falciparum genomic intelligence in Mozambique